Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
Clinical trial NCT05689372 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT05689372
- Sponsor
- Novo Nordisk A/S
- Status
- ENROLLING_BY_INVITATION
- Study type
- OBSERVATIONAL
- Start date
- 2026-02-02
- Primary completion
- 2026-11-30
- Enrollment
- 600
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.